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Data on robotic retroperitoneal lymph node dissection (R‑RPLND) for metastatic testicular germ 
cell tumours (mTGCTs) are scarce and the use of R‑RPLND itself is still under debate. The aim of our 
study was to evaluate the indications, feasibility and outcomes of R‑RPLND, with special emphasis 
on differences between primary R‑RPLND (pR‑RPLND) and post‑chemotherapeutic R‑RPLND (pcR‑
RPLND) in mTGCTs. We retrospectively analysed the data of patients who underwent R‑RPLND 
for mTGCT between November 2013 and September 2019 in two centres in Germany. Indications, 
operative technique, intra‑ and postoperative complications and oncologic outcome were analysed. 
Twenty‑three mTGCT patients underwent R‑RPLND (7 pR‑RPLND, 16 pcR‑RPLND). For pR‑RPLND 
versus pcR‑RPLND, median time of surgery was 243 min [interquartile range (IQR) 123–303] versus 
359 min (IQR 202–440, p = 0.154) and median blood loss 100 mL (IQR 50–200) versus 275 mL (IQR 
100–775, p = 0.018). Intra‑ and postoperative complications were more frequent in pcR‑RPLND (pcR‑
RPLND: intra/post: 44%/44%; pR‑RPLND: intra/post: 0%/29%). However, these were only statistically 
significant in the case of intraoperative complications (intra: p = 0.036, post: p = 0.579). Intraoperative 
complications (n = 7), conversions (n = 4) and transfusions (n = 4) occurred in pcR‑RPLND patients only. 
After a median follow‑up of 16.3 months (IQR 7.5–35.0) there were no recurrences or deaths. R‑RPLND 
displays a valuable, minimally invasive treatment option in mTGCT. However, R‑RPLND is challenging 
and pcR‑RPLND especially bears a considerable risk of complications. This operation should be limited 
to patients with an easily accessible residual tumour mass and to surgeons experienced in robotic 
surgery and TGCT treatment.
Testicular germ cell tumours (TGCTs) affect young men, but the disease itself has an excellent cure  rate1. Retrop-
eritoneal lymph node dissection (RPLND) is an important column of TGCT treatment, though it has a shrinking 
importance in clinical stage (CS)  12–5. Nevertheless, in metastatic TGCT (mTGCT), RPLND remains an integral 
part of treatment in both the primary (p) and post-chemotherapeutic (pc)  setting2,4. To date, RPLND is mainly 
performed by open surgery, and has ever since been associated with a relatively high complication  rate6. With 
the introduction of minimally invasive surgery, promising results were achieved with laparoscopic RPLND 
(L-RPLND)7,8. Due to the technical advantages of robotic surgery, several groups started to transfer the results 
of L-RPLND into robotic RPLND (R-RPLND)9–12. Since the beginning of the development of minimally invasive 
RPLND, concerns have been raised, mainly in terms of perioperative morbidity and oncologic  outcome7,13. It is 
apparent that a minimally invasive approach can only be called successful if its advantages are not outweighed 
by perioperative morbidity and oncologic outcomes.
We thus evaluated the indications, feasibility and outcomes of R-RPLND in mTGCT, with special emphasis 
on differences between pR-RPLND and pcR-RPLND.
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Patients and methods
Patient population. We retrospectively analysed the records of all patients who underwent R-RPLND 
for mTGCT between November 2013 and September 2019 at the Urology Departments of Saarland Univer-
sity Medical Centre, Homburg [n = 18, 11/2013–09/2019, open RPLND: n = 9 (33%)], and Malteser Hospital, 
Bonn, a teaching hospital of the University Hospital Bonn [n = 5, 07/2018–08/2019, open RPLND: n = 0 (0%)]. 
Patients were offered R-RPLND in case of limited retroperitoneal disease and when appearing technically fea-
sible according to preoperative imaging. All patients gave written informed consent and anonymized patient 
data were used. This proceeding was approved by with the ethics committee of Saarland (identification num-
ber: 135/20). All methods were performed in accordance with the relevant guidelines and regulations. Each 
indication for R-RPLND was thoroughly approved according to guidelines, histological findings, clinical stage 
and patient compliance. Staging of the patients was performed according to the current TNM and IGCCCG 
 classifications1,14. In pcR-RPLND patients, standard frontline chemotherapy regimens included bleomycin/
etoposide/cisplatin (n = 14) or cisplatin/etoposide/ifosfamide (n = 2, due to concerns on bleomycin because of 
heavy smoking and/or inhaling drug abuse).
Surgical technique. Operations were performed by five experienced surgeons (C.-H.O., S.S., J.H., M.S., 
M.S.) for open and robotic RPLND. C.-H.O. and S.S. took part in all operations, either as the primary surgeon 
or as supervisor.
The extent of RPLND depended on the primary site of metastasis. Modified RPLND template dissection was 
performed in patients with low-volume disease, limited to the primary landing zone of the affected  testis15–17. 
The right-sided template included the right common iliac, paracaval, precaval, retrocaval, and interaortocaval 
lymph nodes and the right gonadal vein; the left-sided template included the left common iliac, preaortic, para-
aortic, and retroaortic lymph nodes to the level of the inferior mesenteric artery, and the left gonadal  vein16. 
Low volume disease in pcR-RPLND patients was defined according to the extension of lymph node diameter 
after chemotherapy. In all other patients a bilateral, nerve-sparing (whenever possible) template was resected.
The da Vinci Si and X four-arm surgical systems (Intuitive Surgical, Palo Alto, California, USA) were used. 
A transperitoneal approach was applied. For trocar placement in the supine position see Fig. 1.
Afterwards, the patient was placed with the head downward and the legs slightly bent. In addition, the left side 
was rotated 15° downwards, with the system docked from the head of the patient over the left shoulder (Fig. 2).
Access to the retroperitoneum started with the mobilisation of the caecum and ileum by incision of the peri-
toneum. Thus, the colon and small intestines fell away from the operative field. With the third robotic arm the 
peritoneum was retracted. If necessary—i.e., in obese patients or at poor exposure—percutaneous stay sutures 
were placed to keep away the  peritoneum18. After identification of the dissection field margins, the lymph nodes 
(LNs) were removed by the split-and-roll technique, starting from the caudal border at the crossing of the iliac 
artery and  ureter19. Dissection then continued cranially with the precaval and pre-aortal LNs. Inter-aortocaval 
Figure 1.  Port placement. (a) Da Vinci Si: Port placement included three 8-mm trocars—two above the 
anterior superior iliac spine on each side and a third one approximately 8 cm cranially on the left side 
underneath. The camera trocar (12 mm) was placed in the midline, 5 cm below the umbilicus, in line with the 
two 8-mm trocars. For the assistant physician, a 12- and 5-mm trocar was inserted on the right side below the 
costal arch. Port placement was the same for unilateral and/or bilateral cases. (b) Da Vinci X: Port placement 
included four 8-mm da Vinci trocars, including the 8-mm camera trocar (right lower abdomen), inserted in one 
line in the lower abdomen with equivalent distances to each other. For the assistant physician, a 12-mm trocar 
was inserted in the right lower abdomen, even more caudal to the da Vinci trocars. If a unilateral modified 
template is dissected, this approach can be modified according to Stepanian et al., with the line of the robotic 
trocar placement turning towards the aimed  template24. We thank Thomas Gebhardt for creating the figure.
3
Vol.:(0123456789)
Scientific Reports |        (2021) 11:10700  | https://doi.org/10.1038/s41598-021-89823-y
www.nature.com/scientificreports/
LNs were mobilised, starting at the aortic bifurcation, where the sympathetic nerve fibres of the hypogastric 
plexus were identified and secured to achieve a nerve-sparing technique. After mobilisation of the descending 
colon, it was retracted by the assistant port. Paraaortic LNs above the inferior mesenteric artery (IMA) were 
easily accessed from the right side. Ligation and division of the IMA were only needed in selected cases. Access 
to the retrocaval and retroaortic LNs was achieved using vessel loops and a 30° optical lens. Dissected LN tis-
sue of specified resection areas was removed using the 12-mm assistant port or non-permeable retrieval bags.
Assessment of complications and Follow‑up. Intra- and postoperative complications were defined 
as any variation from the usual course. Postoperative complications were assessed using the Clavien–Dindo 
classification  system20. Patient follow-up was performed according to the recommendations of the European 
association of  Urology2. Relapse was defined as elevation of tumour markers or progressive disease on imaging.
Statistical analysis. Continuous variables are shown as medians with interquartile ranges (IQR), and cat-
egorial variables were assessed using frequencies and proportions. Differences between groups were calculated 
with the Mann–Whitney U test for continuous variables and with the  Chi2 test for categorial variables. A p-value 
of < 0.05 was considered statistically significant. Statistical analysis was carried out using SPSS 25 (IBM Corpora-
tion, Armonk, New York, USA).
Results
Baseline patient characteristics. A total of 23 mTGCT patients underwent R-RPLND. Thirteen were 
performed using the da Vinci Si platform and ten were performed using the X platform. Seven (30%) received 
pR-RPLND and 16 (70%) received pcR-RPLND. For baseline and preoperative characteristics, see Table 1.
Most of the patients were nonseminomatous TGCT (NSGCT) patients (78%), predominantly CS 2 (83%) 
with a good prognosis (70%). The main indication for R-RPLND in mTGCT was pc residual mass. All patients 
had normalised tumour markers (AFP, β-HCG, LDH) prior to R-RPLND.
Two seminoma patients underwent pcR-RPLND; one due to life-threatening recurrent septic conditions 
during the first two of three planned cycles of chemotherapy, most probably associated to trisomy 21 (CS 2B 
patient)21; the other one due to a haemodynamic relevant compression of the inferior caval vein by the residual 
tumour (CS 2C).
Three patients relapsed under surveillance in CS 1, one seminoma and two NSGCT patients. Two of them 
(one seminoma, one NSGCT) relapsed with CS IIA (both marker negative) and were treated with pR-RPLND; 
the third patient (NSGCT) relapsed with CS IIB and was treated with chemotherapy. Because of residual tumour 
disease, he underwent pcR-RPLND afterwards. Three seminoma patients received pR-RPLND in CS 2A, two 
at primary diagnosis and one at relapse under surveillance. One NSGCT patient presented with late relapse at 
Figure 2.  Operating room set-up for robotic retroperitoneal lymph node dissection (R-RPLND). We thank 
Thomas Gebhardt for creating the figure.
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5.2 years after chemotherapy for CS 1S disease with a less-than-2-cm mass in the retroperitoneum. All were 
marker-negative at R-RPLND.
Perioperative outcome. In most of the patients, a unilateral modified template was performed (n = 14 
(61%)). The median tumour diameter at R-RPLND was 1.9 cm (IQR 1.7–3.3). Fifteen patients (65%) underwent 
nerve-sparing procedures. For perioperative outcomes, see Table 2.
Median operation time was 303 min (IQR 195–435) in all cases, with 243 min (IQR 123–303) and 359 min 
(IQR 202–440) for pR-RPLND and pcR-RPLND (p = 0.154). Median estimated blood loss was 200 mL (IQR 
100–450), being significantly higher in pcR-RPLND, with 275 mL (IQR 100–775) compared to 100 mL (IQR 
50–200) in pR-RPLND (p = 0.018). Four patients (17%) received blood transfusions (all pcR-RPLND).
Table 1.  Baseline characteristics of patients prior to R-RPLND. yr years, IQR interquartile range, BMI 
body mass index, ASA American Society of Anaesthesiologists, TGCT testicular germ cell tumour, NSGCT 
nonseminomatous germ cell tumour, IGCCCG International Germ cell Cancer Collaborative Group, 
R-RPLND robotic retroperitoneal lymph node dissection, pR-RPLND primary robotic retroperitoneal lymph 
node dissection, pcR-RPLND post-chemotherapeutic robotic retroperitoneal lymph node dissection. a Two 
seminoma patients received pR-RPLND in CS 2A and one patient in CS 2A at relapse under surveillance. 
They either denied radiotherapy/chemotherapy or R-RPLND was performed to gain diagnostic accuracy. The 
patient at relapse in CS 2A was upgraded to CS 2B (pN2) disease after R-RPLND. Of the two other patients 
only one had a vital seminoma metastasis (CS 2A, pN1), the other patient was downgraded to CS 1 disease. 
None of them received further adjuvant treatment and all of them are recurrent free and alive at a median 
follow-up of 12 (IQR 10–18) months. b Two seminoma patients received pcR-RPLND: one trisomy 21 patient 
because of life-threatening intolerance to chemotherapy in CS 2B with only two cycles of chemotherapy being 
administrable and one in CS 2C with haemodynamic relevant compression of the inferior caval vein due to 
the residual tumour mass. In both cases histology revealed necrosis only. c One NSGCT patient presented 
with relapse in the retroperitoneum of less than 2 cm 5.2 years after diagnosis of CS 1S disease treated initially 
with three cycles of chemotherapy. This patient was comprised in the CS 2A and pcR-RPLND patients. Final 







Median age, year (IQR) 43 (23–46) 32 (26–45)
Median BMI, kg/m2 (IQR) 27.2 (19.9–35.3) 27.8 (23.4–31.8)
ASA Score, n (%)
I 3 (43) 5 (31)
II 4 (57) 10 (63)
III 0 (0) 1 (6)
IV, V 0 (0) 0 (0)
Primary site of TGCT 
Left 3 (43) 10 (63)
Right 4 (57) 6 (38)
Primary tumour histology, n (%)
NSGCT 4 (57) 14 (88)
Seminoma parts 5 (71) 8 (50)
Teratoma parts 4 (57) 9 (56)
Yolk sac tumour parts 2 (29) 7 (44)
Embryonal cell carcinoma parts 2 (29) 13 (81)
Chorioncarcinoma parts 0 (0) 3 (19)
Seminoma 3 (43)a 2 (13)b
Clinical stage, n (%)
2Ac 7 (100) 1 (6)
2B 0 (0) 8 (50)
2C 0 (0) 3 (19)
3A 0 (0) 1 (6)
3B 0 (0) 2 (13)
3C 0 (0) 1 (6)
IGCCCG classification, n (%)
Good 7 (100) 9 (56)
Intermediate 0 (0) 5 (31)
Poor 0 (0) 2 (13)
Median largest tumour diameter at R-RPLND, cm (IQR) 1.7 (1.4–1.9) 2.3 (1.8–4.0)
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Table 2.  Peri- and postoperative patient outcome. pR-RPLND primary robotic retroperitoneal lymph node 
dissection, pcR-RPLND post-chemotherapeutic robotic retroperitoneal lymph node dissection, n patient 
number, IQR interquartile range, EBL estimated blood loss, na not applicable, ne not evaluated. *Statistically 
significant p < 0.05. a Lumpectomy was performed in one patient with hemodynamic relevant compression of 
the caval vein by residual tumour of a seminoma. b Complications within 90 d postoperatively according to 









Median operation time, min (IQR) 303 (195–435) 243 (123–303) 359 (202–440) 0.154
Median EBL, ml (IQR) 200 (100–450) 100 (50–200) 275 (100–775) 0.018*
Resection template, n (%)
Bilateral 8 (35) 0 (0) 8 (50)
0.039*
Unilateral modified 14 (61) 7 (100) 7 (44)
Lumpectomya 1 (4) 0 (0) 1 (6)
Nerve-sparing, n (%)
0.172Yes 15 (65) 6 (86) 9 (56)
No 8 (35) 1 (14) 7 (44)
Median nodal yield, n (IQR) 11 (7–26) 11 (6–17) 11 (7–27)
0.49
Bilateral 26 (12–30) na 26 (12–30)
Unilateral modified 12 (8–27) 11 (6–17) 8 (8–16)
Lumpectomya 1 (na) na 1 (na)
Lesion histology, n (%)
ne
Necrosis or normal tissue 8 (25) 2 (29) 6 (38)
Teratoma 6 (26) 1 (14) 5 (31)
Germ cell tumour 9 (39) 4 (57) 5 (31)
Final nodal stage, n (%)
0.298
pN0 8 (35) 2 (29) 6 (28)
pN1 7 (30) 1 (14) 6 (38)
pN2 8 (35) 4 (57) 4 (25)
pN3 0 (0) 0 (0) 0 (0)
Complication rate, n (%)
Intraoperative 7 (30) 0 (0) 7 (44) 0.036*
Postoperativeb 9 (39) 2 (29) 7 (44) 0.493
Intraoperative complications
Bleeding lumbar artery 1 na 1
Partial resection of ureter 1 na 1
Partial resection of ileum 1 na 1
Poor exposure 2 (→ conversion) na 2 (→ conversion)
Ventilation problems 1 (→ conversion) na 1 (→ conversion)
Bleeding renal vein, nephrectomy 1 (→ conversion) na 1 (→ conversion)
Clavien-Dindo Classificationb, n (%)
I 0 0 0
II bleeding with blood  transfusionc 4 0 4
IIIa chylous ascites 1 1 0
 lymphocele 4 1 3
IIIb wound  dehiscenced 1 0 1
 Compartment syndrome left  legd 1 0 1
 Chylous ascites 1 0 1
IVa 0 0 0
IVb 0 0 0
Conversion rate, n (%) 4 (17) 0 (0) 4 (25) 0.146
Transfusion rate, n (%) 4 (17) 0 (0) 4 (25) 0.146
Length of stay, days (IQR) 6 (4–9) 4 (4–9) 6 (5–10) 0.376
Median follow-up, months (IQR) 16.3 (7.5–35.0) 11.5 (7.0–27.4) 19.2 (7.9–35.0) 0.492
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Intraoperative complications occurred only in pcR-RPLND patients (n = 7, 30% compared to n = 0, 0%) 
(p = 0.036). Of them, three were successfully managed robotically—bleeding of a lumbar artery (without indica-
tion for transfusion), partial resection of the left ureter by performing an end-to-end anastomosis and partial 
resection of the ileum by establishing an end-to-end anastomosis. Ureteral injury was due to tumour involve-
ment and bowel injury occurred iatrogenic due to thermal injury. In four cases, conversion to open surgery was 
decided upon. Adhesion of tumour tissue to the renal vein was managed by nephrectomy to prevent further 
blood loss and enabling complete resection of residual tumour tissue. In two of the first patients, poor exposure 
of the retroperitoneum led to conversion. In another patient with large-volume CS 3A disease, anaesthetic ven-
tilation problems marked by subsequently rising pulmonary pressure due to the pneumoperitoneum forced late 
conversion after prolonged operation time.
Postoperative complications occurred in nine patients (39%), of whom seven (30%) had major complications 
(Clavien–Dindo ≥ III; Table 1)—two (29%, all major) patients of the pR-RPLND and seven (44%, five major) of 
the pcR-RPLND group (p = 0.493). The most frequent major complications were chylous ascites and lymphoceles. 
Most of them could be managed by placing a drainage under local anaesthesia. However, in one patient chylascites 
had to be treated by open surgical ligation of the thoracic duct. In two other patients, grade IIIb complications 
occurred—a secondary wound dehiscence in one and a compartment syndrome of the left lower leg in another 
patient, both managed with surgery. Median length of stay was 6 days (IQR 4–9), with four days (IQR 4–9) in 
the pR-RPLND and 6 days (IQR 5–10) in the pcR-RPLND patients (p = 0.376).
Oncologic outcome and follow‑up data. On pathological review, the median nodal yield was 11 (IQR 
7–26); 26 (IQR 12–30) in bilateral and 12 (8–27) in modified unilateral resected templates. The most frequent 
histology was germ cell tumour (GCT) in nine (39%) patients, with GCT (n = 4, 57%) being the most frequent 
histology type in the pR-RPLND and necrosis (n = 6, 38%) being the most frequent in the pcR-RPLND patients. 
Eight patients (35%) had no metastatic lesions (pN0), seven (30%) were classified as pN1 and eight (35%) were 
classified as pN2. In pR-RPLND patients, two (29%) were downgraded to pathological stage (PS) 1 disease, one 
seminoma and one NSGCT patient. Four (57%) of the pR-RPLND patients were upgraded from CS 2A to PS 2B 
(pN2) disease, two seminoma and two NSGCT patients (R-RPLND: teratoma; embryonal cell carcinoma). In 
none of the cases was adjuvant treatment performed. All patients had negative postoperative tumour markers. 
At a median follow-up of 16.3 months (IQR 7.5–35.0) there were no recurrences or deaths in any patients (see 
Table 2).
Discussion
The use of minimally invasive RPLND is still under debate, as concerns regarding morbidity and oncologic 
efficacy exist. Compared to open RPLND, minimally invasive RPLND has the advantage of lower blood loss, 
less pain, shorter length of stay and cosmetic  benefits7–10,12,22. However, laparoscopic RPLND is challenging and 
therefore R-RPLND, with its technical benefits, may overcome the limitations of laparoscopic RPLND.
To date, most of the studies on R-RPLND have reported on pR-RPLND10,18,22–25, with the largest cohort com-
prising 58 patients including mainly CS 1  tumours22. Only a few publications on pcR-RPLND are  available11,12,26,27, 
with the largest series comprising 45  patients27. So far, only one other publication exists on R-RPLND in a mere 
mTGCT patient collective, comprising both pR-RPLND (n = 22) and pcR-RPLND (n = 4)  patients28. Such reports 
define the possibilities of R-RPLND for mTGCT patients, taking into account the nearly vanished relevance of 
pR-RPLND in CS 1 patients, in whom the treatment options nowadays are surveillance or one cycle of chemo-
therapy in high-risk  patients2,3,5. Additionally, no direct comparison between pR-RPLND and pcR-RPLND in 
mTGCT has been made. In the present study, it became evident that pR-RPLND and pcR-RPLND for mTGCT 
may be challenging in different ways. The results of our series of patients demonstrate the feasibility of R-RPLND 
for a wide range of indications, as well as the differently challenging character of pR-RPLND compared to pcR-
RPLND, with acceptable morbidity and excellent early oncologic efficacy in mTGCT patients.
Positioning of the patient and trocars is crucial for optimal exposure, with poor exposure being the most 
frequent reason for conversions in the beginning of our series. We used an approach with the patient in the supine 
position. Alternative positioning included patient in the  flank10–12 or lower lithotomy  position18, with the limita-
tion that only unilateral or modified template resection was possible. The positioning of the patient in the supine 
position, with all of the trocars placed in the lower abdomen, offers ideal access to the retroperitoneum, enabling 
both uni- and bilateral template  resection24. Using this approach, R-RPLND has a broad range of indications in 
mTGCT, ranging from patients primarily presenting CS 2A/B disease to those at relapse under surveillance and 
those with residual disease after chemotherapy, all of whom were included in our analysis.
With a median estimated blood loss of 200 mL, our study demonstrates the minimally invasive nature of the 
 technique12,22. A median time of surgery of 303 min—243 in pR-RPLND and 359 in pcR-RPLND—seems to be 
quite long, however is comparable to the results of  others12,22.
When comparing the pR-RPLND with the pcR-RPLND patient collective, we observed a higher operating 
time, conversion rate, blood loss, transfusion rate and complication rate in the pcR-RPLND patients. In terms 
of statistical significance, only blood loss was higher and intraoperative complications occurred more frequently 
in the pcR-RPLND patients. A direct comparison of pR-RPLND and pcR-RPLND is not available to date. Rocco 
et al. reported an intra- and postoperative complication rate of 3.3% and 33%, respectively, in mainly CS 1 pR-
RPLND  patients22. This is in line with our complication rates, which were 0% for intra- and 29% for postoperative 
complications in the pR-RPLND group. Pc-RPLND is challenging even in open surgery, and bears the risk of 
intraoperative complications and additional  procedures6. Li et al. reported an overall postoperative complica-
tion rate of 32%, including 19% major complications for both pcR-RPLND and open  RPLND12. In total, 20% 
(10% major) of the complications occurred in pcR-RPLND, and 40% (24% major) in open RPLND patients. 
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Other large open RPLND series report on 18% major postoperative complications with vascular injury being 
the most common intraoperative and ileus the most frequent postoperative  complication29. We report a higher 
overall postoperative complication rate of 39% (30% major), comprising both pR-RPLND and pcR-RPLND. 
The most common major postoperative complications in our series were chylous ascites (8%) and lymphoceles 
(17%) that in most cases were easily managed by putting in a drainage. Large studies on open pc-RPLND report 
lower lymphocele rates compared to chylous ascites rates of 3% vs. 13%, with chylascites being the second most 
frequent general postoperative  complication29. Thus patients should be informed about these important com-
plications preoperatively. In our series all intraoperative complications, conversion to open surgery and major 
postoperative complications (Clavien–Dindo ≥ 3b) occurred during the first three years after implementation 
of the technique and in the pcR-RPLND collective only, illustrating that a learning curve is relevant. Thus even 
in a high volume robotic surgery centre (> 600 robotic procedures per year) a learning curve of R-RPLND has 
to be taken into account. Furthermore these results demonstrate that pcR-RPLND is more challenging than 
pR-RPLND. Thus, especially at the implementation of the technique, one has to bear a higher complication rate 
in mind, and starting in patients with limited disease seems reasonable. In summary our results are in line with 
the results of other large volume series on R-RPLND22,27,28.
Tumour size in the retroperitoneum is the most important challenging factor in open pc-RPLND30. This 
might even be more relevant for R-RPLND. According to our experience, patients with limited disease in the 
retroperitoneum are ideal candidates for R-RPLND. The altered desmoplastic tissue after chemotherapy and 
the differences in seminoma and NSGCT histology are additional challenging reasons, even in open  RPLND31. 
However, although limited to two patients, our results demonstrate that pcR-RPLND in special indications is 
feasible even in seminoma patients.
Minimally invasive RPLND series have been criticised for incomplete template dissection. With our position-
ing of the patient in the supine position, all relevant template resections, even bilateral templates, are possible. 
Our median nodal yield was 11, 26 in bilateral and 12 in modified unilateral templates, which is lower than that 
described in other  studies10,12,22. This may be due to the wide variation in indications and resected templates. 
Furthermore, postchemotherapeutic tumours are often large convoluted masses, making nodal count in this 
setting not reliable and highly dependent on the pathologists  expertise32. Concerning pR-RPLND, there are no 
reliable studies on retroperitoneal nodal counts in healthy patients. Additionally, we did not perform a pathologic 
re-review. Traditionally, a wide variation in lymph node yields exists, depending on whether they are performed 
en bloc or in packages and how pathology processing and specimen evaluation are  performed32.
The results reported by Calaway et al. should attract  attention33. They report on five patients that were referred 
to their department after R-RPLND elsewhere, all presenting with recurrences in unusual locations. Reasons for 
this, such as poor patient selection, poor operative technique and surgical technology, are discussed. The median 
time to recurrence was 259 days (range 92–503). In our own series, with a median follow up of 495 days (IQR 
251–933), we have so far seen no recurrences or deaths. Nevertheless, our results need to be validated with a 
longer follow-up period.
As indications for pR-RPLND in CS 1 disease, due to the nowadays most often applied treatment options 
of surveillance or one cycle of chemotherapy, have almost vanished, our study shows the wide indications for 
R-RPLND in mTGCT in a real-world  setting2,3,5. Of note, several patients with special indications were included—
seminoma patients in CS 2A, patients at relapse under surveillance, a patient at late relapse after chemotherapy 
and pc seminoma patients. Of the pR-RPLND mTGCT patients, three were seminomas in CS 2A disease. All 
of these patients denied radiation or chemotherapy, and with the aim of offering an approach that reduces tox-
icities and overtreatment and, in response to the setting of the SEMS and PRIMETEST trials, pR-RPLND was 
 performed34–37. All of these patients were discharged after three to four days. None of them received adjuvant 
treatment and all of them are relapse free at 24, 12 and 9 months, respectively. Even though these results need 
confirmation with longer follow-up and in a prospective setting, they show the possibilities of pR-RPLND in 
mTGCT patients, holding the promise of sparing adjuvant therapies, providing excellent oncologic outcomes 
and at the same time offering a minimally invasive therapy  approach5,38,39.
Concerning pc-RPLND, as reliable prognostic markers for residual disease in RPLND specimens are still 
lacking, we are overtreating up to 40–50% of pc TGCT  patients16. Thus the extent of the dissection and it’s mor-
bidity should be as limited as  possible40,41. This can be achieved with a robot-assisted approach and a limited 
dissection  template41.
There are several limitations to our study, including its retrospective character, the missing evaluation of 
antegrade ejaculation and the pathologic re-evaluation of the number of lymph nodes dissected. Additionally, 
different surgeons were involved in the operations. A larger series and a longer follow-up are needed to further 
determine the role of R-RPLND in mTGCT.
Conclusion
R-RPLND offers a treatment option for mTGCT in both the primary and post-chemotherapeutic setting. PR-
RPLND in mTGCT displays a minimal-invasive treatment option whilst sparing adjuvant therapies associated 
with mortality increasing long-term toxicities. Pc-RPLND is associated with a 40–50% chance of overtreatment. 
The robotic approach offers a minimal-invasive treatment alternative to these patients. PcR-RPLND is more 
challenging than pR-RPLND. Both, pR-RPLND as pcR-RPLND, are providing excellent oncologic outcome in 
the mTGCT patient setting. Carefully chosen mTGCT patients, in the hands of surgeons experienced in TGCT 
treatment and robotic surgery, may profit from minimally invasive R-RPLND.
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